233 related articles for article (PubMed ID: 35943801)
1. DHODH is an independent prognostic marker and potent therapeutic target in neuroblastoma.
Olsen TK; Dyberg C; Embaie BT; Alchahin A; Milosevic J; Ding J; Otte J; Tümmler C; Hed Myrberg I; Westerhout EM; Koster J; Versteeg R; Ding HF; Kogner P; Johnsen JI; Sykes DB; Baryawno N
JCI Insight; 2022 Aug; 7(17):. PubMed ID: 35943801
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic targeting of both dihydroorotate dehydrogenase and nucleoside transport in MYCN-amplified neuroblastoma.
Yu Y; Ding J; Zhu S; Alptekin A; Dong Z; Yan C; Zha Y; Ding HF
Cell Death Dis; 2021 Aug; 12(9):821. PubMed ID: 34462431
[TBL] [Abstract][Full Text] [Related]
3. ENT1 blockade by CNX-774 overcomes resistance to DHODH inhibition in pancreatic cancer.
Mullen NJ; Thakur R; Shukla SK; Chaika NV; Kollala SS; Wang D; He C; Fujii Y; Sharma S; Mulder SE; Sykes DB; Singh PK
Cancer Lett; 2023 Jan; 552():215981. PubMed ID: 36341997
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the de novo pyrimidine biosynthesis pathway limits ribosomal RNA transcription causing nucleolar stress in glioblastoma cells.
Lafita-Navarro MC; Venkateswaran N; Kilgore JA; Kanji S; Han J; Barnes S; Williams NS; Buszczak M; Burma S; Conacci-Sorrell M
PLoS Genet; 2020 Nov; 16(11):e1009117. PubMed ID: 33201894
[TBL] [Abstract][Full Text] [Related]
5. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer.
Madak JT; Bankhead A; Cuthbertson CR; Showalter HD; Neamati N
Pharmacol Ther; 2019 Mar; 195():111-131. PubMed ID: 30347213
[TBL] [Abstract][Full Text] [Related]
6. DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia.
Sexauer AN; Alexe G; Gustafsson K; Zanetakos E; Milosevic J; Ayres M; Gandhi V; Pikman Y; Stegmaier K; Sykes DB
Blood Adv; 2023 Nov; 7(21):6685-6701. PubMed ID: 37648673
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis.
He T; Haapa-Paananen S; Kaminskyy VO; Kohonen P; Fey V; Zhivotovsky B; Kallioniemi O; Perälä M
Oncogene; 2014 Jul; 33(27):3538-49. PubMed ID: 24013224
[TBL] [Abstract][Full Text] [Related]
8. Development of a biomarker to monitor target engagement after treatment with dihydroorotate dehydrogenase inhibitors.
Pontikos MA; Leija C; Zhao Z; Wang X; Kilgore J; Tornesi B; Adenmatten N; Phillips MA; Williams NS
Biochem Pharmacol; 2022 Oct; 204():115237. PubMed ID: 36055381
[TBL] [Abstract][Full Text] [Related]
9. DHODH inhibition represents a therapeutic strategy and improves abiraterone treatment in castration-resistant prostate cancer.
Guo S; Miao M; Wu Y; Pan D; Wu Q; Kang Z; Zeng J; Zhong G; Liu C; Wang J
Oncogene; 2024 May; 43(19):1399-1410. PubMed ID: 38480915
[TBL] [Abstract][Full Text] [Related]
10. Redistribution of defective mitochondria-mediated dihydroorotate dehydrogenase imparts 5-fluorouracil resistance in colorectal cancer.
Dong S; Zhang M; Cheng Z; Zhang X; Liang W; Li S; Li L; Xu Q; Song S; Liu Z; Yang G; Zhao X; Tao Z; Liang S; Wang K; Zhang G; Hu S
Redox Biol; 2024 Jul; 73():103207. PubMed ID: 38805974
[TBL] [Abstract][Full Text] [Related]
11. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors.
Vyas VK; Ghate M
Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807
[TBL] [Abstract][Full Text] [Related]
12. A carboxylic acid isostere screen of the DHODH inhibitor Brequinar.
DeRatt LG; Christine Pietsch E; Tanner A; Shaffer P; Jacoby E; Wang W; Kazmi F; Zhang X; Attar RM; Edwards JP; Kuduk SD
Bioorg Med Chem Lett; 2020 Nov; 30(22):127589. PubMed ID: 33007394
[TBL] [Abstract][Full Text] [Related]
13. A novel mitochondria-targeting DHODH inhibitor induces robust ferroptosis and alleviates immune suppression.
Hai Y; Fan R; Zhao T; Lin R; Zhuang J; Deng A; Meng S; Hou Z; Wei G
Pharmacol Res; 2024 Apr; 202():107115. PubMed ID: 38423231
[TBL] [Abstract][Full Text] [Related]
14. Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties.
Cao L; Weetall M; Trotta C; Cintron K; Ma J; Kim MJ; Furia B; Romfo C; Graci JD; Li W; Du J; Sheedy J; Hedrick J; Risher N; Yeh S; Qi H; Arasu T; Hwang S; Lennox W; Kong R; Petruska J; Moon YC; Babiak J; Davis TW; Jacobson A; Almstead NG; Branstrom A; Colacino JM; Peltz SW
Mol Cancer Ther; 2019 Jan; 18(1):3-16. PubMed ID: 30352802
[TBL] [Abstract][Full Text] [Related]
15. Identification of DHODH as a therapeutic target in small cell lung cancer.
Li L; Ng SR; Colón CI; Drapkin BJ; Hsu PP; Li Z; Nabel CS; Lewis CA; Romero R; Mercer KL; Bhutkar A; Phat S; Myers DT; Muzumdar MD; Westcott PMK; Beytagh MC; Farago AF; Vander Heiden MG; Dyson NJ; Jacks T
Sci Transl Med; 2019 Nov; 11(517):. PubMed ID: 31694929
[TBL] [Abstract][Full Text] [Related]
16. A novel series of human dihydroorotate dehydrogenase inhibitors discovered by in vitro screening: inhibition activity and crystallographic binding mode.
Zeng T; Zuo Z; Luo Y; Zhao Y; Yu Y; Chen Q
FEBS Open Bio; 2019 Aug; 9(8):1348-1354. PubMed ID: 31087527
[TBL] [Abstract][Full Text] [Related]
17. Brequinar derivatives and species-specific drug design for dihydroorotate dehydrogenase.
Hurt DE; Sutton AE; Clardy J
Bioorg Med Chem Lett; 2006 Mar; 16(6):1610-5. PubMed ID: 16406782
[TBL] [Abstract][Full Text] [Related]
18. SAR studies toward discovery of emvododstat (PTC299), a potent dihydroorotate dehydrogenase (DHODH) inhibitor.
Baiazitov RY; Qi H; Arasu T; Lennox W; Cao L; Weetall M; Furia B; Zhuo J; Choi S; Kim MJ; Sheedy J; Davis T; Moon YC
Eur J Med Chem; 2022 Dec; 244():114826. PubMed ID: 36242990
[TBL] [Abstract][Full Text] [Related]
19. Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells.
Mohamad Fairus AK; Choudhary B; Hosahalli S; Kavitha N; Shatrah O
Biochimie; 2017 Apr; 135():154-163. PubMed ID: 28196676
[TBL] [Abstract][Full Text] [Related]
20. Functional expression of human dihydroorotate dehydrogenase (DHODH) in pyr4 mutants of ustilago maydis allows target validation of DHODH inhibitors in vivo.
Zameitat E; Freymark G; Dietz CD; Löffler M; Bölker M
Appl Environ Microbiol; 2007 May; 73(10):3371-9. PubMed ID: 17369345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
